Schizophrenia, Undifferentiated Type
Conditions
Keywords
Schizophrenic Disorders, Schizophrenia, Affect, Emotional Blunting
Brief summary
After an initial screening visit, including an assessment of psychiatric disorders, patients stabilized on antipsychotic medication (aripiprazole or risperidone) for at least 6 weeks and control subjects will undergo an assessment using functional magnetic resonance imaging (fMRI) of the differences of patterns of brain activation during an emotional task
Detailed description
This study is: interventional, comparative, open label, multi center, without experimental treatment. Main objective: To evaluate the effect of aripiprazole and risperidone on brain activation during an emotional task of matching patients with schizophrenia, and in reference to control subjects. Secondary Objective: Comparison of emotional subjective and physiological perception in patients with schizophrenia in relation with their treatment. Comparison of brain activation in patients during the emotional induction task based on symptomatic dimensions, personality traits and performance on cognitive and attentional tests, and for insight capacity . Comparison of transcript level of candidate genes in blood mononuclear cells between the study groups and study the interactions between the observed differences in brain imaging and different levels of transcription of these genes.
Interventions
OTHERImagery
All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
GENETICpharmacogenetic sampling
A pharmacogenetic sample will be done with an additional consentment.
Sponsors
Qualissima
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* For patients 1. Men and women, right handed, 18 to 45 years; 2. Having given their written informed consent; 3. Presenting a diagnosis of schizophrenia made by DMS IV, hospitalized or followed regularly in a hospital proper, and whose symptoms are stable for at least 6 weeks, at the discretion of the psychiatrist; 4. Receiving antipsychotic treatment (risperidone or aripiprazole) monotherapy stable (treatment and dose) for at least than 6 weeks; 5. Showing no contra-indication for fMRI; 6. Patients whose physical examination is unremarkable clinically significant; 7. Patients without serious somatic pathology; 8. Affiliated to a social security system. 9. For women of childbearing potential, an appropriate contraception is mandatory and an negative pregnancy test * For controls 1. Men and women, right handed, aged 18 to 45 years of age, sex and socio-educational level comparable to patients included; 2. Having given their written informed consent; 3. Do not present a diagnosis of schizophrenia according to DSM IV set; 4. Do not present psychiatric history, and free of any psychotropic medication; 5. Including the physical examination is unremarkable clinically significant; 6. Having no professional musical practice; 7. Affiliated with a social security system.
Exclusion criteria
* For patients 1. Patients in menstruation without effective contraception (oral, intramuscular hormonal, intrauterine device, or surgical); 2. Patients who are pregnant or breastfeeding; 3. Patients not meeting criteria for schizophrenia according to DSM IV criteria or those with resistant schizophrenia (Kane criteria); 4. Introducing a somatic disease or serious neurological, particularly Parkinson's disease, epilepsy, tardive dyskinesia and disabling cardiovascular disease, liver or kidney disease; 5. Presenting a contra-indication to MRI; 6. Having a history of alcoholism or drug addiction during the past year; 7. Participating in another clinical trial or are in a period of exclusion from a previous protocol; 8. Patients likely to have behavioral self aggression from the trial investigators During the study: <!-- --> 1. The investigator considers, for safety reasons, it is in the interest of the patient to be excluded from the study (Hospital readmission due to psychotic symptoms, clinical or psychiatric reasons) 2. Consentment withdrawal 3. The patient does not longer correspond to the inclusion criteria or protocol requirements * For controls 1. Women of childbearing potential without effective contraception (oral, intramuscular hormonal, intrauterine device, or surgical); 2. Pregnant or breastfeeding; 3. Presenting a somatic, psychiatric or neurological disorder; 4. Presenting a history of alcohol or substance abuse during the past year; 5. Participating in another clinical trial or are in a period of exclusion from a previous protocol; 6. Presenting a contra-indication to MRI.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) | 3 days after the decision of inclusion | During the fMRI session, the activation of each brain circuits is measured by a Bold signal (an arbitrary measure of contrast: numbers of voxels highlighted/activated in the region of interest). The emotional task is composed by congruent and incongruent images. Three effects were caused by the task: congruence, attention and valence effects. Each of them affect, involve and activate the regions of interests differentially within the differents arms. The region of interests who were mainly observed are: Anterior Cingulate Cortex (ACC), Prefrontal dorso-lateral Cortex (PFdlC) and the Amygdala (A). |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of Emotional Reactivity | 3 days after the decision of inclusion |
| Assessment of Cognitive and Attentional Abilities | 3 days after the decision of inclusion |
| Assessment of Personality Traits | 3 days after the decision of inclusion |
| Investigate the Level of Expression of Candidate Genes | one blood sample |
Countries
France
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Aripiprazole Schizophrenic patient stabilized under aripiprazole for six weeks before inclusion | 17 |
| Risperidone Schizophrenic patient stabilized under risperidone for six weeks before inclusion | 14 |
| Control healthy volunteers | 36 |
| Total | 67 |
Baseline characteristics
| Characteristic | Risperidone | Control | Aripiprazole | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 14 Participants | 36 Participants | 17 Participants | 67 Participants |
| Age, Continuous | 31.6 years STANDARD_DEVIATION 9.2 | 32.9 years STANDARD_DEVIATION 7.8 | 34.6 years STANDARD_DEVIATION 9.6 | 33.1 years STANDARD_DEVIATION 8.5 |
| Region of Enrollment France | 14 participants | 36 participants | 17 participants | 67 participants |
| Sex: Female, Male Female | 4 Participants | 12 Participants | 8 Participants | 24 Participants |
| Sex: Female, Male Male | 10 Participants | 24 Participants | 9 Participants | 43 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 17 | 0 / 14 | 1 / 36 |
| serious Total, serious adverse events | 0 / 17 | 0 / 14 | 0 / 36 |
Outcome results
Primary
Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI)
During the fMRI session, the activation of each brain circuits is measured by a Bold signal (an arbitrary measure of contrast: numbers of voxels highlighted/activated in the region of interest). The emotional task is composed by congruent and incongruent images. Three effects were caused by the task: congruence, attention and valence effects. Each of them affect, involve and activate the regions of interests differentially within the differents arms. The region of interests who were mainly observed are: Anterior Cingulate Cortex (ACC), Prefrontal dorso-lateral Cortex (PFdlC) and the Amygdala (A).
Time frame: 3 days after the decision of inclusion
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Aripiprazole | Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) | Activation of Anterior Cingulate Cortex (ACC) | -0.25 arbitrary units of activation | Standard Error 2.8 |
| Aripiprazole | Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) | Activation of Prefrontal dorso-lateral Cortex (PF) | 0.2 arbitrary units of activation | Standard Error 3 |
| Risperidone | Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) | Activation of Anterior Cingulate Cortex (ACC) | -0.21 arbitrary units of activation | Standard Error 3.1 |
| Risperidone | Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) | Activation of Prefrontal dorso-lateral Cortex (PF) | -0.3 arbitrary units of activation | Standard Error 4 |
| Control | Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) | Activation of Anterior Cingulate Cortex (ACC) | 3.8 arbitrary units of activation | Standard Error 3.2 |
| Control | Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) | Activation of Prefrontal dorso-lateral Cortex (PF) | 5.3 arbitrary units of activation | Standard Error 5 |
Secondary
Assessment of Cognitive and Attentional Abilities
Time frame: 3 days after the decision of inclusion
Secondary
Assessment of Emotional Reactivity
Time frame: 3 days after the decision of inclusion
Secondary
Assessment of Personality Traits
Time frame: 3 days after the decision of inclusion
Secondary
Investigate the Level of Expression of Candidate Genes
Time frame: one blood sample